Allison Barz Leahy, MD Allison Barz Leahy, MD, is a fellow with the Cancer Immunotherpay Program at Children's Hospital of Philadelphia. Locations: Main Campus Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467) Education and Training Medical SchoolMD - SUNY Upstate Medical University, Syracuse, NY InternshipMedicine - Children’s Hospital of Philadelphia, Philadelphia, PA ResidencyMedicine - Children’s Hospital of Philadelphia, Philadelphia, PA FellowshipPediatric Hematology/Oncology - Children’s Hospital of Philadelphia, Philadelphia, PA Pediatric Hospital Epidemiology and Outcomes Research Training Program - Children’s Hospital of Philadelphia, Philadelphia, PA Board CertificationPediatricsGraduate DegreeMA in Biological Sciences - Hunter College of the City of New York, New York, NY Titles and Academic Titles Fellow Departments and Services Cancer Immunotherapy Program Publications Papers2017 Hill D, Leahy AB, Sciasci J, O’Neill S, Reilly A, Balamuth N, Seeholzer S, Spergel J, Brown-Whitehorn T. Medication contaminants as a potential cause of anaphylaxis to vincristine. Pediatr Blood Cancer. 2017 Aug 22. Epub ahead of print. 2016 Basch E, Deal A, Kris MG, Scher H, Hudis C, Sabbatini P, Rogak L, Bennett A, Dueck A, Atkinson T, Chou J, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan J, Schrag D. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2016 Feb 20; 34(6):557-65. 2014 Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep 29;106(9) 2013 Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, et al. Feasibility of Long-Term Patient Self- Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. J Clin Oncol. 2013 Jul 10;31(20):2580-5. 2009 Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris M, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. Journal of the National Cancer Institute. 2009 Dec 101(23): 1624-1632. 2007 Basch E, Iasonos A, Barz A, Culkin A, Kris M, Artz D, Fearn P, Speakman J, Scher H, McCabe M, Schrag D. Online symptom self-reporting by lung cancer patients using the Common Terminology Criteria for Adverse Events (CTCAE). Journal of Clinical Oncology. 2007 Dec 25(34): 5374-80. Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher H, McCabe M, Schrag D. Evaluation of an online platform for cancer patient selfreporting of chemotherapy toxicities. Journal of the American Medical Informatics Association. 2007 May 14(3): 264-268. 2006 Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. The Lancet Oncology. 2006 Nov 7(11): 883-4. 2004 Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady M, Roy P, Song Y, Canchola R, Barz A, Bolognia J, Eng S, Elahi A, Begg CB. Estimating the relative risk of developingmelanoma in INK4A carriers. European Journal of Cancer Prevention. 2004 Feb 13(1): 65- 70. 2001 Orlow I, Roy P, Barz A, Canchola R, Song Y, Berwick M. Validation of denaturing high performance liquid chromatograph as a rapid detection method for the identification of human INK4A gene mutations. Journal of Molecular Diagnostics. 2001 Nov 3(4): 158-63. Abstracts2017 Getz K, Sung L, Ky B, Gerbing R, Leger K, Leahy AB, Sack L, Woods W, Alonzo T, Gamis A, Aplenc R. Incidence and Predictors of Anthracycline Cardiotoxicity among Children Treated on the AAML0531 Clinical Trial: A Report from the Children’s Oncology Group. Submitted to ASH Annual Meeting 2017. Posters and PresentationsInvited Lectures 2017 Leahy AB. “Gabapentin as an antiemetic” – Children’s Oncology Group Cancer Control Webinar. September 2017. Awards and Honors 2017-present, Recipient of NIH Loan Repayment Program in Pediatric Research 2017-2018, American Society of Hematology Clinical Research Training Program Fellow 2011, Dracker Family Scholarship 2011, Jack J. Schneider Scholarship 2011, Commendation, outstanding performance in clinical years, SUNY Upstate College of Medicine 2011, Gold Humanism Honor Society 2011, Alpha Omega Alpha Editorial and Academic Positions Editorial Positions 2017, Reviewer, Cancer 2017, Reviewer, Journal of Clinical Oncology Academic and Institutional Committees 2016-present, Lead, Quality Improvement Project: Patient-reported outcomes in outpatient oncology. Division of Oncology, 2016-present, Fellow Liaison, Pediatric Hematology/Oncology Fellowship Leadership and Memberships Memberships in Professional Organizations International 2017-present, International Society for Quality of Life Research National 2017-present, American College of Epidemiology 2017-present, American Society of Hematology 2016-present, American Society of Pediatric Hematology and Oncology 2015-present, Children’s Oncology Group 2014-present, American Society of Clinical Oncology Patient Experience Ratings About the Patient Experience Rating System The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question. Responses are measured on a scale of 1 to 5 with 5 being the best score. We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments. Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care. The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.